The IMROZstudy is a large phase three international trial that included centers in China and focused on newly diagnosed transplant-ineligible multiple myeloma patients. The primary goal was to assess the clinical value of adding isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (bor...
The IMRO study is a large phase three international trial that included centers in China and focused on newly diagnosed transplant-ineligible multiple myeloma patients. The primary goal was to assess the clinical value of adding isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (bo...
We completed a retrospective case series assessing outcomes of 187 MM patients who received this regimen at our institution. The 100-day non-relapse mortality incidence was zero. Before auto-HCT, 9.6 and 52.9% of patients achieved a complete response (CR) or >= very good partial response (VG...
Two cycles of consolidation therapy included 1800 mg of daratumumab once every 2 weeks plus the same dosing regimen of VRd. During maintenance, 1800 mg of daratumumab was given once every 4 weeks in combination with 10 mg of lenalidomide per day. The primary end point was PFS. Key secondary...
(NCT03652064), the addition of daratumumab and hyaluronidase-fihj (subcutaneous daratumumab; Darzalex Faspro) to the VRd regimen (bortezomib, lenalidomide, and dexamethasone) improved minimal residual disease (MRD) negativity rates compared to VRd alone in newly diagnosed multiple myeloma patients w...
Clinical Study on Treatment of Multiple Myeloma with Yishen Huoxue Jiedu(益肾活血解毒汤)Decoction Combined with VRD Regimen 在线阅读 免费下载 引用 收藏 分享 摘要 目的:探讨“髓毒”理论指导下益肾活血解毒汤联合VRD方案(硼替佐米+地塞米松+来那度胺)治疗多发性骨髓瘤的有效性及安全性。方法:选择126例...
Chakraborty R, Muchtar E, Kumar S, Buadi FK, Dingli D, Dispenzieri A, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transpl. 2017;52:34–40. ...
(Revlimid), and dexamethasone—a regimen known as VRd—was efficacious and tolerable in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), according to findings from the phase 2 GEM-BELA-VRD trial (NCT04802356) presented at the 21st Annual International Myeloma Society ...
regimen potentially improves progression-free survival in the frontline, transplant-eligible population and supports the potential of this quadruplet to become a new standard-of-care induction regimen in this treatment setting,” said Hartmut Goldschmidt, MD, president of GMMG, professor of medicine ...
We performed multivariate Cox regression analysis to evaluate the impact of several important variables, including age, sex, race, immunoglobulin subtype, light chain, ISS, cytogenetic risk, conditioning regimen, post-transplant therapy, and best final response, on PFS and OS. Results: We identified...